Abstract: The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments. The present disclosure provides compounds of Formula (I).

Abstract: Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.

Abstract: POZ-lipid conjugates and lipid nanoparticles (LNPs) including POZ-lipid conjugates used to facilitate delivery of an encapsulated payload. LNPs including POZ-lipid conjugates and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing a PEG-lipid.

Abstract: The present invention provides a scalable synthesis of enantiomerically pure brivaracetam, and related derivatives.

Abstract: The present invention relates to a peptide compound of PDL2 selected from a peptide fragment, a functional homologue, and a functional analogue, as well as to a nucleic acid, such as DNA or RNA, encoding the peptide compound, a vector, such as a virus vector, and a host cell, such as mammalian cell, comprising the vector. The peptide compound, nucleic acid, vector and host cell of the present invention are in particular, useful for the treatment or prevention of a cancer characterized by expression of PDL2.

Abstract: Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier.

Abstract: Provided herein are anti-inflammatory nanofibers and methods of use thereof. In particular methods are provided for the use of anti-inflammatory nanofibers in the promotion of tissue (e.g., urinary bladder tissue) regeneration.

Abstract: In a method of killing or reducing a growth of methicillin-resistant Staphylococcus aureus (S. aureus), a composition including a peptide consisting of the amino acid sequence of SEQ ID NO:2 or 3 is administered to a subject in need thereof. The peptide can be usefully applied as an active ingredient for antibiotics, cosmetic compositions, food additives, feed additives, biological pesticides and quasi-drugs.

Abstract: This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of chronic weight management, obesity and/or blood glucose control, including but not limited to dual agonist peptide product of SEQ ID NO. 1.

Abstract: Provided herein are phosphatidylethanolamine (PE)-specific probes and methods of use thereof. In particular, the present invention provides conjugates of PE binding moieties with detectable markers, and methods of use thereof to detect and/or characterize PE within cells.

Abstract: A human insulin-like growth factor (IGF) binding protein stock solution and method of making the same include a non-recombinant human IGF binding protein-3 (nr-IGFBP-3) in an aqueous buffered medium. The concentration of the nr-IGFBP-3 in the stock solution ranges from about 16 micrograms per milliliter (?g/ml) to about 40 ?g/ml. A kit includes a set of calibrators for nr-IGFBP-3. The set of calibrators includes the nr-IGFBP-3 in different concentrations.

Abstract: Disclosed are methods and compositions for the treatment of autism spectrum disorder, related disorders and symptoms of such disorders, comprising co-administration of an oxytocin peptide and magnesium ions. Co-administration of an oxytocin peptide and magnesium ions results in a synergistic or enhanced effect on reducing social and communication deficits in a patient suffering from an autism spectrum disorder.

Abstract: The invention provides a first concentrate comprising lactate and calcium ions, said first concentrate having increased stability against precipitation at temperatures around +4° C., said first concentrate being useful for preparing a ready-to-use dialysis fluid by mixing said first concentrate with water and optionally a second concentrate comprising glucose, wherein that the lactate concentration Lconc (expressed in moles per litre, M) of the concentrate fulfills the conditions: a) Lconc>0.8 M; and b) Lconc<(1.9?0.4×Caready) M; and wherein Caready is the calcium concentration of the ready-to-use dialysis fluid expressed in millimoles per litre (mM).

Abstract: An enzyme with an acyl transfer function has an amino acid sequence identical to a SEQ ID NO:1, which is capable of acylation modification for macrolactins, filipins macrolides, chloramphenicol, and glycosylated piericidin A. An application of an acyltransferase of the present invention is to bind an acyl group of an acyl donor to macrolide compounds, chloramphenicol and glycosylated piericidins. The enzyme with the acyl transfer function can improve pharmacological activity of the macrolide compounds through acylation reaction of macrolactins, thereby improving bioavailability, enhancing efficacy, and reducing toxic as well as side effects, which provides a new strategy for the drug development of macrolide compounds.

Abstract: The present invention relates to a pharmaceutical composition for treating gout and a gout treatment kit. According to an embodiment of the present invention, a pharmaceutical composition for treating gout comprising a probe containing at least one or more peptides specifically coupled to a monosodium urate (MSU) crystals and a first enzyme which is coupled to the probe and reacts with the target MSU crystal coupled to the probe or urea of surrounding joint fluid to remove the target MSU crystal is provided.

Abstract: The present invention is directed to methods of treating hypertriglyceridemia or hypertriglyceridemia-related diseases in a subject by using recombinant PRAP1 polypeptides. According to some embodiments of the present disclosure, the subject is a human, in which the recombinant PRAP1 polypeptide comprises the amino acid sequence 100% identical to SEQ ID NO: 1 or 2. According to certain embodiments of the present disclosure, the subject is a mouse, in which the recombinant PRAP1 polypeptide comprises the amino acid sequence 100% identical to SEQ ID NO: 3 or 4.

Abstract: Methods of recovering cannabinoids from cell cultures include methods comprising steps of separating the cell culture at a temperature above the melting point of the cannabinoid to separate a light phase comprising liquid state cannabinoid from a heavy phase; and methods comprising treating the cell culture at a temperature below the melting point of the cannabinoid to separate a light phase from a heavy phase comprising solid state cannabinoid. Other methods include contacting the culture with a water-miscible solvent to form a water-miscible phase and an aqueous phase, separating the two phases and recovering the cannabinoid. Other methods include contacting the culture with a water-immiscible solvent to form a water-immiscible phase and an aqueous phase, separating the two phases, and recovering the cannabinoid. Other methods include washing the inner surface of a fermentation vessel with alkaline solution to recover cannabinoid attached to the vessel surface.

Abstract: The present disclosure reaches a method of a unique combination of bioinformatic technical tools together with chemical synthesis for identification of bioactive peptide molecules based on non-ribosomal peptide synthetases. Those bioactive cyclic peptide molecules are useful as antimicrobials, anticancer agents, antiparasitic, immunosuppressants, and others. Series of useful cyclic peptides and the pharmaceutical compositions thereof are within the scope of this disclosure.

Abstract: The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.

Abstract: The present invention relates to a new peptide called Antisecretory Factor (AF) 17 which is an isolated recombinant and/or synthetically produced which has a t½ of at least 1.8 h. The peptide is e.g. useful for normalizing pathological fluid transport and/or inflammatory reactions in animals and in humans. AF-17 and pharmaceutical compositions of AF-17 can e.g. be used for treating and/or preventing TBI and/or secondary brain injuries associated with TBI, as well as for treating and/or preventing acquired brain injuries and to optimize cancer treatment.